Retinal vascular occlusions

IU Scott, PA Campochiaro, NJ Newman, V Biousse - The Lancet, 2020 - thelancet.com
Acute retinal vascular occlusions are common causes of visual impairment. Although both
retinal artery occlusions and retinal vein occlusions are associated with increased age and …

Anti-VEGF-resistant retinal diseases: a review of the latest treatment options

JO Wallsh, RP Gallemore - Cells, 2021 - mdpi.com
Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in
the treatment of numerous retinal diseases, most notably exudative age-related macular …

Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)

U Schmidt-Erfurth, J Garcia-Arumi, BS Gerendas… - …, 2019 - karger.com
The high prevalence of cardiovascular disease particularly in the elderly population is
associated with retinal vascular disease. Retinal vein occlusions represent severe …

Diabetic macular oedema

GS Tan, N Cheung, R Simó, GCM Cheung… - The lancet Diabetes & …, 2017 - thelancet.com
Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is
the most common form of sight-threatening retinopathy in people with diabetes. It affects one …

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion

JA Haller, F Bandello, R Belfort Jr, MS Blumenkranz… - Ophthalmology, 2010 - Elsevier
OBJECTIVE: To evaluate the safety and efficacy of dexamethasone intravitreal implant (DEX
implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss …

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study

WL Clark, DS Boyer, JS Heier, DM Brown, JA Haller… - Ophthalmology, 2016 - Elsevier
Purpose To determine week 52 efficacy and safety outcomes in eyes with macular edema
after branch retinal vein occlusion (BRVO) treated with 2 mg intravitreal aflibercept injection …

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

DM Brown, PA Campochiaro, RB Bhisitkul, AC Ho… - Ophthalmology, 2011 - Elsevier
PURPOSE: Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg
ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO) …

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results

JA Haller, F Bandello, R Belfort Jr, MS Blumenkranz… - Ophthalmology, 2011 - Elsevier
OBJECTIVE: To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone
intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing to …

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study

PA Campochiaro, WL Clark, DS Boyer, JS Heier… - Ophthalmology, 2015 - Elsevier
Purpose To compare the efficacy and safety of intravitreal aflibercept injection (IAI) with
macular grid laser photocoagulation for the treatment of macular edema after branch retinal …

Natural history of branch retinal vein occlusion: an evidence-based systematic review

SL Rogers, RL McIntosh, L Lim, P Mitchell, N Cheung… - Ophthalmology, 2010 - Elsevier
OBJECTIVE: To describe the natural history of branch retinal vein occlusion (BRVO) based
on the best available evidence from the literature. CLINICAL RELEVANCE: Branch retinal …